ID   EPM2A_MOUSE             Reviewed;         330 AA.
AC   Q9WUA5; G5E8E2; Q8BY80;
DT   19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   03-OCT-2012, sequence version 2.
DT   03-AUG-2022, entry version 157.
DE   RecName: Full=Laforin {ECO:0000303|PubMed:16971387};
DE            EC=3.1.3.- {ECO:0000269|PubMed:16971387, ECO:0000269|PubMed:18040046, ECO:0000269|PubMed:24430976};
DE            EC=3.1.3.16;
DE            EC=3.1.3.48 {ECO:0000269|PubMed:16971387};
DE   AltName: Full=Glucan phosphatase;
DE   AltName: Full=Lafora PTPase;
DE            Short=LAFPTPase;
GN   Name=Epm2a;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   STRAIN=ICR; TISSUE=Brain;
RX   PubMed=10092504; DOI=10.1006/bbrc.1999.0402;
RA   Ganesh S., Amano K., Delgado-Escueta A.V., Yamakawa K.;
RT   "Isolation and characterization of mouse homologue for the human epilepsy
RT   gene, EPM2A.";
RL   Biochem. Biophys. Res. Commun. 257:24-28(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S., She X.,
RA   Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W., Kapustin Y.,
RA   Meric P., Maglott D., Birtle Z., Marques A.C., Graves T., Zhou S.,
RA   Teague B., Potamousis K., Churas C., Place M., Herschleb J., Runnheim R.,
RA   Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z., Lindblad-Toh K.,
RA   Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of the
RT   mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 10-137.
RC   STRAIN=C57BL/6J; TISSUE=Thymus;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J.,
RA   Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R.,
RA   Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T.,
RA   Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A.,
RA   Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B.,
RA   Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M.,
RA   Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S.,
RA   Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D.,
RA   Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M.,
RA   Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H.,
RA   Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V.,
RA   Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S.,
RA   Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H.,
RA   Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N.,
RA   Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F.,
RA   Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G.,
RA   Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z.,
RA   Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S.,
RA   Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K.,
RA   Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R.,
RA   van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H.,
RA   Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M.,
RA   Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C.,
RA   Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S.,
RA   Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K.,
RA   Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M.,
RA   Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C.,
RA   Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A.,
RA   Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [5]
RP   DEVELOPMENTAL STAGE.
RX   PubMed=11355878; DOI=10.1006/bbrc.2001.4914;
RA   Ganesh S., Agarwala K.L., Amano K., Suzuki T., Delgado-Escueta A.V.,
RA   Yamakawa K.;
RT   "Regional and developmental expression of Epm2a gene and its evolutionary
RT   conservation.";
RL   Biochem. Biophys. Res. Commun. 283:1046-1053(2001).
RN   [6]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=12019206; DOI=10.1093/hmg/11.11.1251;
RA   Ganesh S., Delgado-Escueta A.V., Sakamoto T., Avila M.R., Machado-Salas J.,
RA   Hoshii Y., Akagi T., Gomi H., Suzuki T., Amano K., Agarwala K.L.,
RA   Hasegawa Y., Bai D.S., Ishihara T., Hashikawa T., Itohara S.,
RA   Cornford E.M., Niki H., Yamakawa K.;
RT   "Targeted disruption of the Epm2a gene causes formation of Lafora inclusion
RT   bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired
RT   behavioral response in mice.";
RL   Hum. Mol. Genet. 11:1251-1262(2002).
RN   [7]
RP   SUBUNIT, CATALYTIC ACTIVITY, MUTAGENESIS OF TRP-32; PHE-83; ARG-107;
RP   THR-193; CYS-265; GLN-292; TYR-293 AND PRO-300, AND ACTIVE SITE.
RX   PubMed=16971387; DOI=10.1074/jbc.m607778200;
RA   Liu Y., Wang Y., Wu C., Liu Y., Zheng P.;
RT   "Dimerization of Laforin is required for its optimal phosphatase activity,
RT   regulation of GSK3beta phosphorylation, and Wnt signaling.";
RL   J. Biol. Chem. 281:34768-34774(2006).
RN   [8]
RP   FUNCTION AS A GLUCAN PHOSPHATASE, CATALYTIC ACTIVITY, DISRUPTION PHENOTYPE,
RP   ACTIVE SITE, AND MUTAGENESIS OF TRP-32 AND CYS-265.
RX   PubMed=18040046; DOI=10.1073/pnas.0707952104;
RA   Tagliabracci V.S., Turnbull J., Wang W., Girard J.M., Zhao X., Skurat A.V.,
RA   Delgado-Escueta A.V., Minassian B.A., Depaoli-Roach A.A., Roach P.J.;
RT   "Laforin is a glycogen phosphatase, deficiency of which leads to elevated
RT   phosphorylation of glycogen in vivo.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:19262-19266(2007).
RN   [9]
RP   FUNCTION IN GLYCOGEN METABOLISM, AND DISRUPTION PHENOTYPE.
RX   PubMed=18852261; DOI=10.1074/jbc.m807428200;
RA   Tagliabracci V.S., Girard J.M., Segvich D., Meyer C., Turnbull J., Zhao X.,
RA   Minassian B.A., Depaoli-Roach A.A., Roach P.J.;
RT   "Abnormal metabolism of glycogen phosphate as a cause for Lafora disease.";
RL   J. Biol. Chem. 283:33816-33825(2008).
RN   [10]
RP   FUNCTION, AND COMPLEX FORMATION WITH NHLRC1 AND HSP70.
RX   PubMed=19036738; DOI=10.1093/hmg/ddn398;
RA   Garyali P., Siwach P., Singh P.K., Puri R., Mittal S., Sengupta S.,
RA   Parihar R., Ganesh S.;
RT   "The malin-laforin complex suppresses the cellular toxicity of misfolded
RT   proteins by promoting their degradation through the ubiquitin-proteasome
RT   system.";
RL   Hum. Mol. Genet. 18:688-700(2009).
RN   [11]
RP   FUNCTION, INTERACTION WITH MAPT, AND DISRUPTION PHENOTYPE.
RX   PubMed=19542233; DOI=10.1074/jbc.m109.009688;
RA   Puri R., Suzuki T., Yamakawa K., Ganesh S.;
RT   "Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an
RT   animal model for Lafora disease.";
RL   J. Biol. Chem. 284:22657-22663(2009).
RN   [12]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=20453062; DOI=10.1093/hmg/ddq190;
RA   Aguado C., Sarkar S., Korolchuk V.I., Criado O., Vernia S., Boya P.,
RA   Sanz P., de Cordoba S.R., Knecht E., Rubinsztein D.C.;
RT   "Laforin, the most common protein mutated in Lafora disease, regulates
RT   autophagy.";
RL   Hum. Mol. Genet. 19:2867-2876(2010).
RN   [13]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=22669944; DOI=10.1074/jbc.m111.331611;
RA   Tiberia E., Turnbull J., Wang T., Ruggieri A., Zhao X.C., Pencea N.,
RA   Israelian J., Wang Y., Ackerley C.A., Wang P., Liu Y., Minassian B.A.;
RT   "Increased laforin and laforin binding to glycogen underlie Lafora body
RT   formation in malin-deficient Lafora disease.";
RL   J. Biol. Chem. 287:25650-25659(2012).
RN   [14]
RP   DISRUPTION PHENOTYPE, AND FUNCTION.
RX   PubMed=23663739; DOI=10.1016/j.cmet.2013.04.006;
RA   Nitschke F., Wang P., Schmieder P., Girard J.M., Awrey D.E., Wang T.,
RA   Israelian J., Zhao X., Turnbull J., Heydenreich M., Kleinpeter E.,
RA   Steup M., Minassian B.A.;
RT   "Hyperphosphorylation of glucosyl C6 carbons and altered structure of
RT   glycogen in the neurodegenerative epilepsy Lafora disease.";
RL   Cell Metab. 17:756-767(2013).
RN   [15]
RP   INTERACTION WITH PPP1R3D.
RX   PubMed=23624058; DOI=10.1016/j.biocel.2013.04.019;
RA   Rubio-Villena C., Garcia-Gimeno M.A., Sanz P.;
RT   "Glycogenic activity of R6, a protein phosphatase 1 regulatory subunit, is
RT   modulated by the laforin-malin complex.";
RL   Int. J. Biochem. Cell Biol. 45:1479-1488(2013).
RN   [16]
RP   FUNCTION, CATALYTIC ACTIVITY, MUTAGENESIS OF CYS-265, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=24430976; DOI=10.1093/brain/awt353;
RA   Gayarre J., Duran-Trio L., Criado Garcia O., Aguado C., Juana-Lopez L.,
RA   Crespo I., Knecht E., Bovolenta P., Rodriguez de Cordoba S.;
RT   "The phosphatase activity of laforin is dispensable to rescue Epm2a-/-mice
RT   from Lafora disease.";
RL   Brain 137:806-818(2014).
RN   [17]
RP   FUNCTION.
RX   PubMed=24068615; DOI=10.1007/s12035-013-8546-z;
RA   Liu Y., Zeng L., Ma K., Baba O., Zheng P., Liu Y., Wang Y.;
RT   "Laforin-malin complex degrades polyglucosan bodies in concert with
RT   glycogen debranching enzyme and brain isoform glycogen phosphorylase.";
RL   Mol. Neurobiol. 49:645-657(2014).
CC   -!- FUNCTION: Plays an important role in preventing glycogen
CC       hyperphosphorylation and the formation of insoluble aggregates, via its
CC       activity as glycogen phosphatase, and by promoting the ubiquitination
CC       of proteins involved in glycogen metabolism via its interaction with
CC       the E3 ubiquitin ligase NHLRC1/malin (PubMed:18040046, PubMed:18852261,
CC       PubMed:19036738, PubMed:23663739, PubMed:24430976, PubMed:24068615).
CC       Dephosphorylates phosphotyrosine and synthetic substrates, such as
CC       para-nitrophenylphosphate (pNPP), and has low activity with
CC       phosphoserine and phosphothreonine substrates (in vitro)
CC       (PubMed:16971387, PubMed:24430976). Has also been shown to
CC       dephosphorylate MAPT (PubMed:19542233). Shows strong phosphatase
CC       activity towards complex carbohydrates in vitro, avoiding glycogen
CC       hyperphosphorylation which is associated with reduced branching and
CC       formation of insoluble aggregates (PubMed:18040046, PubMed:18852261,
CC       PubMed:23663739). Forms a complex with NHLRC1/malin and HSP70, which
CC       suppresses the cellular toxicity of misfolded proteins by promoting
CC       their degradation through the ubiquitin-proteasome system (UPS)
CC       (PubMed:19036738, PubMed:24068615). Acts as a scaffold protein to
CC       facilitate PPP1R3C/PTG ubiquitination by NHLRC1/malin. Also promotes
CC       proteasome-independent protein degradation through the macroautophagy
CC       pathway (PubMed:20453062). {ECO:0000269|PubMed:16971387,
CC       ECO:0000269|PubMed:18040046, ECO:0000269|PubMed:18852261,
CC       ECO:0000269|PubMed:19036738, ECO:0000269|PubMed:19542233,
CC       ECO:0000269|PubMed:20453062, ECO:0000269|PubMed:22669944,
CC       ECO:0000269|PubMed:23663739, ECO:0000269|PubMed:24068615,
CC       ECO:0000269|PubMed:24430976}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + O-phospho-L-tyrosyl-[protein] = L-tyrosyl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:10684, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620; EC=3.1.3.48; Evidence={ECO:0000255|PROSITE-
CC         ProRule:PRU10044, ECO:0000269|PubMed:16971387};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + O-phospho-L-seryl-[protein] = L-seryl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:20629, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15377, ChEBI:CHEBI:29999, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:83421; EC=3.1.3.16;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + O-phospho-L-threonyl-[protein] = L-threonyl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:47004, Rhea:RHEA-COMP:11060, Rhea:RHEA-
CC         COMP:11605, ChEBI:CHEBI:15377, ChEBI:CHEBI:30013, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:61977; EC=3.1.3.16;
CC   -!- SUBUNIT: Homodimer (PubMed:16971387). Interacts with PPP1R3B, PPP1R3C,
CC       HIRIP5, and EPM2AIP1 (By similarity). Binds glycogen and Lafora bodies.
CC       Interacts with NHLRC1/malin (via the NHL repeats) (By similarity).
CC       Forms a complex with NHLRC1/malin and HSP70 (PubMed:19036738).
CC       Interacts with PPP1R3D; in the presence of NHLC1/malin the interaction
CC       leads to ubiquitination and autophagic degradation of PPP1R3D
CC       (PubMed:23624058). Interacts (via the phosphatase domain) with
CC       MAPT/Tau; the interaction dephosphorylates MAPT (PubMed:19542233).
CC       Interacts with PRDM8 (By similarity). {ECO:0000250|UniProtKB:O95278,
CC       ECO:0000269|PubMed:16971387, ECO:0000269|PubMed:19036738,
CC       ECO:0000269|PubMed:19542233, ECO:0000269|PubMed:23624058}.
CC   -!- INTERACTION:
CC       Q9WUA5; Q9WV60: Gsk3b; NbExp=2; IntAct=EBI-1040928, EBI-400793;
CC       Q9WUA5; Q6VVB1: NHLRC1; Xeno; NbExp=12; IntAct=EBI-1040928, EBI-6426628;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:O95278}.
CC       Endoplasmic reticulum membrane {ECO:0000250|UniProtKB:O95278};
CC       Peripheral membrane protein {ECO:0000250|UniProtKB:O95278}; Cytoplasmic
CC       side {ECO:0000250|UniProtKB:O95278}. Cell membrane
CC       {ECO:0000250|UniProtKB:O95278}. Note=Colocalizes with glycogen synthase
CC       in punctate structures in the cytoplasm. Primarily associated with
CC       polyribosomes at the rough endoplasmic reticulum, and also detected at
CC       the plasma membrane. Under glycogenolytic conditions localizes to the
CC       nucleus. {ECO:0000250|UniProtKB:O95278}.
CC   -!- TISSUE SPECIFICITY: Detected in skeletal muscle and in brain (at
CC       protein level) (PubMed:24430976). Widely expressed. Higher levels of
CC       expression are found in heart, brain, liver, skeletal muscle and kidney
CC       (PubMed:10092504). {ECO:0000269|PubMed:10092504,
CC       ECO:0000269|PubMed:24430976}.
CC   -!- DEVELOPMENTAL STAGE: In the embryo, highly expressed at 17 dpc.
CC       Detected in all postnatal stages, but highest expression is found at
CC       day 160 after birth. {ECO:0000269|PubMed:11355878}.
CC   -!- DOMAIN: The CBM20 domain mediates binding to cytoplasmic glycogen and
CC       to Lafora polyglucosan bodies. {ECO:0000250|UniProtKB:O95278}.
CC   -!- PTM: Polyubiquitinated by NHLRC1/malin. {ECO:0000250|UniProtKB:O95278}.
CC   -!- PTM: Phosphorylation on Ser-25 by AMPK affects the phosphatase activity
CC       of the enzyme and its ability to homodimerize and interact with NHLRC1,
CC       PPP1R3C or PRKAA2. {ECO:0000250|UniProtKB:O95278}.
CC   -!- DISRUPTION PHENOTYPE: Impaired behavioral responses, ataxia,
CC       spontaneous myoclonic seizures and progressive accumulation of poorly-
CC       branched, insoluble forms of glycogen (Lafora bodies) in liver, brain
CC       and skeletal muscle tissue (PubMed:12019206, PubMed:18040046,
CC       PubMed:24430976). Expression of both wild-type Epm2a and mutated Epm2a
CC       without phosphatase activity can abolish the appearance of Lafora
CC       bodies in brain and heart from 7 to over 12 month old mutant mice
CC       (PubMed:24430976). At 3 months of age, overall glycogen levels are
CC       normal; by 9 months of age, a 3-fold increase in overall glycogen
CC       levels and a 6-fold increase in glycogen phosphate levels is observed
CC       (PubMed:18040046, PubMed:18852261, PubMed:22669944, PubMed:23663739).
CC       Muscle glycogen has an altered structure, with a reduced size, an
CC       abnormally high proportion of very short side chains, fewer medium-
CC       length chains and an increased number of long chains (PubMed:23663739).
CC       Glycogen synthase (Gys1) and 1,4-alpha-glucan-branching enzyme (Gbe1)
CC       activities in brain and muscle tissue are normal (PubMed:18040046). 10
CC       month old mice have neurofibrillary tangles (NFTs, aggregates of
CC       hyperphosphorylated Mapt/Tau) in brain and muscle tissue, however NFTs
CC       are not observed in 4 and 6 month old mice (PubMed:19542233). 3- and
CC       12- month old mice show reduced numbers of autophagosomes in liver
CC       extracts, and 3-month old starved mice have increased levels of the
CC       autophagy dysfunction marker Map1lc3b/LC3-II and increased levels of
CC       ubiquitinated proteins, suggesting impaired macroautophagy
CC       (PubMed:20453062). {ECO:0000269|PubMed:12019206,
CC       ECO:0000269|PubMed:18040046, ECO:0000269|PubMed:18852261,
CC       ECO:0000269|PubMed:19542233, ECO:0000269|PubMed:20453062,
CC       ECO:0000269|PubMed:22669944, ECO:0000269|PubMed:23663739,
CC       ECO:0000269|PubMed:24430976}.
CC   -!- SIMILARITY: Belongs to the protein-tyrosine phosphatase family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF124044; AAD26336.1; -; mRNA.
DR   EMBL; AC101984; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC157018; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH466562; EDL03516.1; -; Genomic_DNA.
DR   EMBL; AK041609; BAC31004.1; -; mRNA.
DR   CCDS; CCDS23698.1; -.
DR   RefSeq; NP_034276.2; NM_010146.2.
DR   AlphaFoldDB; Q9WUA5; -.
DR   SMR; Q9WUA5; -.
DR   BioGRID; 199484; 3.
DR   IntAct; Q9WUA5; 3.
DR   MINT; Q9WUA5; -.
DR   STRING; 10090.ENSMUSP00000066050; -.
DR   CAZy; CBM20; Carbohydrate-Binding Module Family 20.
DR   PhosphoSitePlus; Q9WUA5; -.
DR   PaxDb; Q9WUA5; -.
DR   PRIDE; Q9WUA5; -.
DR   ProteomicsDB; 275632; -.
DR   Antibodypedia; 19839; 527 antibodies from 38 providers.
DR   DNASU; 13853; -.
DR   Ensembl; ENSMUST00000069106; ENSMUSP00000066050; ENSMUSG00000055493.
DR   GeneID; 13853; -.
DR   KEGG; mmu:13853; -.
DR   UCSC; uc007ejv.1; mouse.
DR   CTD; 7957; -.
DR   MGI; MGI:1341085; Epm2a.
DR   VEuPathDB; HostDB:ENSMUSG00000055493; -.
DR   eggNOG; KOG1716; Eukaryota.
DR   GeneTree; ENSGT00390000010101; -.
DR   HOGENOM; CLU_076792_0_0_1; -.
DR   InParanoid; Q9WUA5; -.
DR   OMA; HLYKDCG; -.
DR   OrthoDB; 865142at2759; -.
DR   PhylomeDB; Q9WUA5; -.
DR   TreeFam; TF332841; -.
DR   BioGRID-ORCS; 13853; 6 hits in 71 CRISPR screens.
DR   ChiTaRS; Epm2a; mouse.
DR   PRO; PR:Q9WUA5; -.
DR   Proteomes; UP000000589; Chromosome 10.
DR   RNAct; Q9WUA5; protein.
DR   Bgee; ENSMUSG00000055493; Expressed in hindlimb stylopod muscle and 81 other tissues.
DR   Genevisible; Q9WUA5; MM.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0098554; C:cytoplasmic side of endoplasmic reticulum membrane; IDA:MGI.
DR   GO; GO:0098556; C:cytoplasmic side of rough endoplasmic reticulum membrane; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IMP:MGI.
DR   GO; GO:0030425; C:dendrite; IDA:MGI.
DR   GO; GO:0005654; C:nucleoplasm; ISO:MGI.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0043204; C:perikaryon; IDA:MGI.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005844; C:polysome; ISO:MGI.
DR   GO; GO:0030246; F:carbohydrate binding; ISS:UniProtKB.
DR   GO; GO:0019203; F:carbohydrate phosphatase activity; IDA:MGI.
DR   GO; GO:0004373; F:glycogen (starch) synthase activity; IEP:MGI.
DR   GO; GO:2001069; F:glycogen binding; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:MGI.
DR   GO; GO:0017018; F:myosin phosphatase activity; IEA:UniProtKB-EC.
DR   GO; GO:0016791; F:phosphatase activity; IDA:MGI.
DR   GO; GO:0004721; F:phosphoprotein phosphatase activity; IDA:MGI.
DR   GO; GO:0030247; F:polysaccharide binding; IDA:MGI.
DR   GO; GO:0046983; F:protein dimerization activity; ISO:MGI.
DR   GO; GO:0042803; F:protein homodimerization activity; ISO:MGI.
DR   GO; GO:0004722; F:protein serine/threonine phosphatase activity; IDA:MGI.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; IDA:MGI.
DR   GO; GO:0008138; F:protein tyrosine/serine/threonine phosphatase activity; TAS:MGI.
DR   GO; GO:2001070; F:starch binding; IDA:MGI.
DR   GO; GO:0000045; P:autophagosome assembly; IMP:MGI.
DR   GO; GO:0006914; P:autophagy; IMP:MGI.
DR   GO; GO:0006816; P:calcium ion transport; IMP:MGI.
DR   GO; GO:0046835; P:carbohydrate phosphorylation; IMP:MGI.
DR   GO; GO:0044260; P:cellular macromolecule metabolic process; IMP:MGI.
DR   GO; GO:0016311; P:dephosphorylation; ISO:MGI.
DR   GO; GO:0014009; P:glial cell proliferation; IGI:MGI.
DR   GO; GO:0005978; P:glycogen biosynthetic process; IDA:MGI.
DR   GO; GO:0005977; P:glycogen metabolic process; IMP:MGI.
DR   GO; GO:0046959; P:habituation; IMP:MGI.
DR   GO; GO:0015813; P:L-glutamate transmembrane transport; IMP:MGI.
DR   GO; GO:0007005; P:mitochondrion organization; IMP:MGI.
DR   GO; GO:0045786; P:negative regulation of cell cycle; IMP:MGI.
DR   GO; GO:0035305; P:negative regulation of dephosphorylation; ISO:MGI.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:MGI.
DR   GO; GO:0033137; P:negative regulation of peptidyl-serine phosphorylation; IMP:MGI.
DR   GO; GO:0010923; P:negative regulation of phosphatase activity; ISO:MGI.
DR   GO; GO:0032007; P:negative regulation of TOR signaling; ISO:MGI.
DR   GO; GO:0007399; P:nervous system development; IMP:MGI.
DR   GO; GO:0035335; P:peptidyl-tyrosine dephosphorylation; ISO:MGI.
DR   GO; GO:0046838; P:phosphorylated carbohydrate dephosphorylation; ISS:UniProtKB.
DR   GO; GO:0016239; P:positive regulation of macroautophagy; IMP:MGI.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IMP:MGI.
DR   GO; GO:0006470; P:protein dephosphorylation; ISO:MGI.
DR   GO; GO:0001558; P:regulation of cell growth; IMP:MGI.
DR   GO; GO:0010468; P:regulation of gene expression; IMP:MGI.
DR   GO; GO:2000465; P:regulation of glycogen (starch) synthase activity; IMP:MGI.
DR   GO; GO:0042325; P:regulation of phosphorylation; IMP:MGI.
DR   GO; GO:0061136; P:regulation of proteasomal protein catabolic process; IMP:MGI.
DR   GO; GO:0042306; P:regulation of protein import into nucleus; IDA:MGI.
DR   GO; GO:0045859; P:regulation of protein kinase activity; IMP:MGI.
DR   GO; GO:1903076; P:regulation of protein localization to plasma membrane; IGI:MGI.
DR   GO; GO:0001932; P:regulation of protein phosphorylation; IMP:MGI.
DR   GO; GO:0031396; P:regulation of protein ubiquitination; IGI:MGI.
DR   GO; GO:1904666; P:regulation of ubiquitin protein ligase activity; IMP:MGI.
DR   GO; GO:0016055; P:Wnt signaling pathway; IMP:MGI.
DR   CDD; cd05806; CBM20_laforin; 1.
DR   CDD; cd14526; DSP_laforin-like; 1.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.90.190.10; -; 1.
DR   InterPro; IPR013784; Carb-bd-like_fold.
DR   InterPro; IPR034831; CBM20_laforin.
DR   InterPro; IPR002044; CBM_fam20.
DR   InterPro; IPR045204; DSP_laforin-like.
DR   InterPro; IPR000340; Dual-sp_phosphatase_cat-dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR042942; Laforin.
DR   InterPro; IPR029021; Prot-tyrosine_phosphatase-like.
DR   InterPro; IPR016130; Tyr_Pase_AS.
DR   InterPro; IPR000387; Tyr_Pase_dom.
DR   InterPro; IPR020422; TYR_PHOSPHATASE_DUAL_dom.
DR   PANTHER; PTHR46864; PTHR46864; 1.
DR   Pfam; PF00686; CBM_20; 1.
DR   Pfam; PF00782; DSPc; 1.
DR   SMART; SM01065; CBM_2; 1.
DR   SMART; SM00195; DSPc; 1.
DR   SUPFAM; SSF49452; SSF49452; 1.
DR   SUPFAM; SSF52799; SSF52799; 1.
DR   PROSITE; PS51166; CBM20; 1.
DR   PROSITE; PS00383; TYR_PHOSPHATASE_1; 1.
DR   PROSITE; PS50056; TYR_PHOSPHATASE_2; 1.
DR   PROSITE; PS50054; TYR_PHOSPHATASE_DUAL; 1.
PE   1: Evidence at protein level;
KW   Autophagy; Carbohydrate metabolism; Cell membrane; Cytoplasm;
KW   Endoplasmic reticulum; Glycogen metabolism; Hydrolase; Membrane;
KW   Phosphoprotein; Protein phosphatase; Reference proteome; Ubl conjugation.
FT   CHAIN           1..330
FT                   /note="Laforin"
FT                   /id="PRO_0000094839"
FT   DOMAIN          1..123
FT                   /note="CBM20"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00594"
FT   DOMAIN          155..322
FT                   /note="Tyrosine-protein phosphatase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00160"
FT   MOTIF           265..271
FT                   /note="Glucan phosphatase signature motif CXAGXGR"
FT                   /evidence="ECO:0000250|UniProtKB:O95278"
FT   ACT_SITE        265
FT                   /note="Phosphocysteine intermediate"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00160,
FT                   ECO:0000269|PubMed:16971387, ECO:0000269|PubMed:18040046"
FT   BINDING         32
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:O95278"
FT   BINDING         86
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:O95278"
FT   BINDING         102..106
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:O95278"
FT   BINDING         196
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:O95278"
FT   BINDING         234
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:O95278"
FT   BINDING         240
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:O95278"
FT   BINDING         266..271
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:O95278"
FT   BINDING         303
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:O95278"
FT   SITE            328
FT                   /note="Required for homodimerization"
FT                   /evidence="ECO:0000250|UniProtKB:O95278"
FT   MOD_RES         25
FT                   /note="Phosphoserine; by AMPK"
FT                   /evidence="ECO:0000250|UniProtKB:O95278"
FT   MUTAGEN         32
FT                   /note="W->G: Loss of glycogen phosphatase activity. Nearly
FT                   abolishes phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:16971387,
FT                   ECO:0000269|PubMed:18040046"
FT   MUTAGEN         83
FT                   /note="F->L: Abolishes phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:16971387"
FT   MUTAGEN         107
FT                   /note="R->C: Abolishes phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:16971387"
FT   MUTAGEN         193
FT                   /note="T->I: Nearly abolishes phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:16971387"
FT   MUTAGEN         265
FT                   /note="C->S: Loss of phosphatase activity with glycogen and
FT                   synthetic substrates."
FT                   /evidence="ECO:0000269|PubMed:16971387,
FT                   ECO:0000269|PubMed:18040046, ECO:0000269|PubMed:24430976"
FT   MUTAGEN         292
FT                   /note="Q->L: Abolishes phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:16971387"
FT   MUTAGEN         293
FT                   /note="Y->N: Nearly abolishes phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:16971387"
FT   MUTAGEN         300
FT                   /note="P->L: Abolishes phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:16971387"
FT   CONFLICT        140
FT                   /note="H -> R (in Ref. 1; AAD26336)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   330 AA;  36958 MW;  89B18C64BBBAB02A CRC64;
     MLFRFGVVVP PAVAGARQEL LLAGSRPELG RWEPHGAVRL RPAGTAAGAA ALALQEPGLW
     LAEVELEAYE EAGGAEPGRV DTFWYKFLQR EPGGELHWEG NGPHHDRCCT YNEDNLVDGV
     YCLPVGHWIE ATGHTNEMKH TTDFYFNIAG HQAMHYSRIL PNIWLGSCPR QLEHVTIKLK
     HELGVTAVMN FQTEWDIIQN SSGCNRYPEP MTPDTMMKLY KEEGLSYIWM PTPDMSTEGR
     VQMLPQAVCL LHALLENGHT VYVHCNAGVG RSTAAVCGWL HYVIGWNLRK VQYFIMAKRP
     AVYIDEDALA QAQQDFSQKF GKVHSSICAL
//
